The ‘warm’ Vaccine Formula Has The Ability To Cope With All Variations
In the study published on July 15, scientists belonging to the general prosperous scientific and research organization (CSIRO) have evaluated the effectiveness of heat-resistant vaccine formulas with Indian Science Institute (IISC) and Mynvax Biotechnology Company developed, while affirming this 'warm' vaccine in accordance with remote locations effectively against all variants of SARS-COV-20: 00 / 1: 05 namqua experimental in mice, scientists discovered the formulas of the "warm" vaccine activated the strong immune response against all variations of SARS-COV-2 like alpha, beta, Gamma and Delta. Notably, these vaccine formulas are still stable at 37 degrees Celsius in 1 month and at 100 degrees C in 90 minutes. Comparison with other vaccines, the vaccine of Pfizer / Biontech must be stored in specialized cold storage At -70 degrees, while Astrazeneca's vaccine must be held from 2 to 8 degrees, causing two vaccines that are not suitable for remote areas and restrictions on resources. Data collected by CSIRO will be used to be used to MYNVAX's choice of formulas into clinical trials on people in India at the end of 2021.Lan Phuong (VNA)
